Technologies and Solutions bejond imagination for follwing segments:
Innovative Interior Heating Solutions
Cutting Edge Ice Protections Systems
Innovative Heating Solutions
Innovative heating systems for batteries
Cutting Edge Solutions for Ice Protection
Newest technology for lightning protection
Cutting edge technology for air disinfection
Individual solutions and our developments
Innovations and Development
LEA®’s operating principle is the electrokinetic inactivation of pathogens. With the aid of a scalable, flat matrix of special microelectrodes, LEA®’s electronic control unit creates an electric field that delivers repeated and powerful kinetic and electric shocks to attack viruses, bacteria and mould spores. These repetitive electrical impacts, delivered at a frequency of varying polarity, destroy the pathogens’ cell structure and render them harmless Pathogens with particle sizes down to 0.1µm are inactivated at a rate of up to 99.99992%. Unlike conventional ionization – or cold plasma-based systems, LEA® produces no dielectric barrier or corona discharges, thus completely avoiding the emission of harmful by-products such as ozone or NOx.
MS2 Bacteriophage
Substitute for influenza, SARS-CoV-2 and other RNA viruses
Result
Rate of reduction achieved: – 99,99992% in 90 minutes
This shows that LEA® can effectively reduce and inactivate airborne influenza, SARS-CoV-2 and other RNA viruses.
Klebsiella aerogenes
Substitute for Klebsiella pneumoniae – a hospital germ that can cause severe pneumonia, urinary tract infections or sepsis.
Rate of reduction achieved: -99,99967% in 45 minutes
This shows that LEA® can effectively reduce and inactivate airborne Klebsiella pneumoniae.
Staphylococcus epidermidis
Substitute for methicillin-resistant Staphylococcus aureus (MRSA) – a common cause of hospital-acquired infections.
Rate of reduction achieved: -99,99993% in 90 minutes
This shows that LEA® can effectively reduce and inactivate airborne Methicillin-resistant Staphylococcus aureus (MRSA).
ASPERGILLUS BRASILIENSIS NIGER
Toxic black mould
Rate of reduction achieved: -99,9958% in 60 minutes
This shows that LEA® can effectively reduce and inactivate airborne toxic black mould.
Test to prove that LEA® emits no harmful ozone and presents no risk to the user.
Ozone concentration over the course of the whole test period: ≤0.001 ppm.
The test showed that no detectable ozone levels were produced by LEA® during the trial.
LEA® was originally intended for use in medical installations, more specifically for use in patient rooms and on the ward. Hospital safety and hygiene regulations require that the highest standards of indoor air quality be maintained in patient rooms. This can require the use of air purification systems. However, conventional systems are mostly unsuitable. Devices with integrated passive filters, e.g. HEPA filters, generate increased noise levels of at least 35dBA, due to the disturbance of airflow during operation. With other technologies such as UV, ionization or non-thermal plasma, ozone or NOx production cannot be completely ruled out. LEA® was developed in order to meet the highest required levels of safety and patient comfort and to avoid the disadvantages associated with conventional systems described above.
Proven to operate completely without the emission of by-products such as ozone or NOx, and featuring extremely quiet operation, LEA® sets new standards of safety and comfort – for patient rooms as well as for many other types of indoor environment.
LEA® makes it simple and cost-efficient to enhance the performance air disinfection systems and air purifiers. Conventional pathogen-reduction technologies can be replaced or upgraded using LEA®, with its unique combination of highly efficient disinfection rates and reliable operation. LEA® will safely boost the performance of your existing appliance to a completely new level with zero emissions of ozone and NOx.
Can be fitted anywhere
The homogeneous buildup of the LEA® microelectrode matrix ensures that it can be laid out to fit any geometry. . It can be integrated into any system architecture through the installation of individually shaped panels equipped with microelectrodes. These bespoke panels may be either flat or curved to match the shape of the underlying structure. This flexibility ensures that LEA® can be integrated fully into any architecture no matter what its shape or dimensions.
LEA® was developed during the Covid-19 pandemic, at a time when air disinfection was seen as of vital importance. The concept for an innovative technology designed to reduce the risk of infection in medical installations was presented to the European Commission. A contract for development was issued shortly thereafter.
A scientific basis for the technology was developed in collaboration with an international team of doctors and microbiologists as part of the EU Horizon2020 “CleanAir” project. This enabled further steps such as the construction of prototypes and the implementation of laboratory tests and medical field tests.
The test results were very promising. It quickly became clear that LEA® has the potential to set new standards for air disinfection technology efficiency. An international patent has therefore been registered.
We now want to offer other OEMs the opportunity to incorporate the benefits of LEA® technology into their own products and solutions.
© • All rights reserved
Imprint | Privacy Policy